Immunome Research

Immunome Research
Open Access

ISSN: 1745-7580


Atsushi Natsume

Atsushi Natsume
Nagoya University School of Medicine,

  • Review
    Chimeric Antigen Receptor Therapeutic Strategies: The Future of Glioblastoma Management
    Author(s): Atsushi Natsume and Courtney PendletonAtsushi Natsume and Courtney Pendleton

    The field of adoptive cellular therapy, using autologous T-cells modified ex vivo to specifically target tumor cells prior to being reintroduced to the patient, has become a new focus of research endeavors searching for a novel and efficacious treatment for oncologic disease, including glioblastoma. Chimeric Antigen Receptor (CAR)-T-cells consist of a single chain variable fragment of a monoclonal antibody coupled with extant T-cell intracellular signaling cascade systems using a viral vector ex vivo. This provides the advantage of targeting tumor specific surface markers, while minimizing off-target effects and potential toxicity. Additionally, the CAR T-cells bypass the need for MHC-restricted presentation, a system which is frequently down-regulated in tumor cells. Among the surface antigens described as targets for CAR T-cell therapy for GBMs, Epidermal growth fa.. View More»
    DOI: 10.4172/1745-7580.1000148

    Abstract PDF

Relevant Topics